Active Implants Corporation Announces Vice President Global Research & Development

Share this story with your network

MEMPHIS, Tenn.–(BUSINESS WIRE)–Active Implants Corporation (AIC), the leader in cushion-bearing technology for orthopedics, today announced that Thomas B. (Tiger) Buford has joined the executive management team as its new Vice President, Global Research & Development. Mr. Buford will be responsible for all research and development activities for all products and systems worldwide.

Mr. Buford has deep and broad expertise in the orthopedic industry and has brought over 50 orthopedic devices to the marketplace. Mr. Buford has achieved success with the world’s leading orthopedic companies at each successive level of responsibility throughout his career. He began his career as a product development engineer with Smith & Nephew plc and progressed through a series of positions of increasing responsibilities with Sulzer Orthopedics, Wright Medical Technology, Inc., and most recently as Vice President, Research & Development with NovaLign Orthopaedics, Inc., an early stage medical device company. Mr. Buford earned a Bachelor of Science degree in mechanical engineering from the University of Memphis. He is a patent holder for total joint devices.

“Tiger is a proven leader with a twenty-five year record of successfully commercializing orthopedic technology and products,” stated Michael R. Mainelli, President & CEO of Active Implants. ”We are excited about his exceptional background, drive, and character and are delighted to have him on our team.”

About Active Implants Corporation

Active Implants Corporation is a privately-held company headquartered in Memphis, TN with research facilities in Netanya, Israel. The company is the leader in developing cushion-bearing technology for the orthopedic industry. TriboFit® Hip System, the company’s first product, is a Class III approved CE mark device and is being sold throughout Europe. NUsurface® Meniscus Implant, the company’s second product designed to treat meniscal deficiency, has also obtained CE mark and is in early studies in Europe.

Leave a Comment

Your email address will not be published. Required fields are marked *

*